Pilot Study of Origanum majoranaTea on Oxidant/Antioxidant Stress Biomarkers in Parkinson disorder North-African Volunteers

Randomized, Placebo-Controlled Pilot Study of Origanum majorana Tea on Oxidant/Antioxidant Stress Biomarkers in Parkinson Idiopathic disorder North-African Patients Volunteers

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202205801626909

Enrollment

Registered

2022-05-12

Start date

2022-05-09

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases Nutritional, Metabolic, Endocrine

Interventions

Experimental Group

Control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: .Age of 40–80 years old .Diagnosis of PD MDS criteria 2015 .Hoehn and Yahr stage less than 4 .Treatment with dose and regimen unchanged for at least 12 weeks prior to screening .No nutritional supplements intake

Exclusion criteria

Exclusion criteria: The absence during the second visit (ie; Day31 of the study) The non-consumption of the Omt or the placebo tea at least one time. Patients had a history of cardiovascular disease, diabetes, renal dysfunction, asthma, food allergies, liver or major gastrointestinal problems or hypertension.

Design outcomes

Primary

Measure	Time frame
SOD	—

Secondary

Measure	Time frame
Catalase ,Carbonylated proteins and Uric acid	—

Countries

Tunisia

Contacts

Public ContactChahra Chbili

Metabolic Biophysics Applied Pharmacology Laboratory

chahrachbili@yahoo.fr+21693645001

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026